Overview

  • Product name

    Anti-Cytokeratin 1 antibody
    See all Cytokeratin 1 primary antibodies
  • Description

    Rabbit polyclonal to Cytokeratin 1
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Mouse, Human
    Predicted to work with: Chimpanzee
  • Immunogen

    Recombinant fragment (His-tag) corresponding to Human Cytokeratin 1 aa 487-644. (Expressed in E.coli).
    Sequence:

    EGEESRMSGECAPNVSVSVSTSHTTISGGGSRGGGGGGYGSGGSSYGSGG GSYGSGGGGGGGRGSYGSGGSSYGSGGGSYGSGGGGGGHGSYGSGSSSGG YRGGSGGGGGGSSGGRGSGGGSSGGSIGGRGSSSGGVKSSGGSSSVKFVS TTYSGVTR


    Database link: P04264

  • Positive control

    • IHC-P: Human kidney, breast cancer and liver cancer tissues. WB: A-375, NCI-H460 and HeLa cell lysates; Recombinant human Cytokeratin 1 protein.

Properties

Applications

Our Abpromise guarantee covers the use of ab232685 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.5 - 2 µg/ml. Predicted molecular weight: 66 kDa.
IHC-P Use a concentration of 5 - 20 µg/ml.

Target

  • Function

    May regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein kinase C (RACK1/GNB2L1).
  • Tissue specificity

    The source of this protein is neonatal foreskin. The 67-kDa type II keratins are expressed in terminally differentiating epidermis.
  • Involvement in disease

    Defects in KRT1 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
    Defects in KRT1 are the cause of ichthyosis hystrix Curth-Macklin type (IHCM) [MIM:146590]. IHCM is a genodermatosis with severe verrucous hyperkeratosis. Affected individuals manifest congenital verrucous black scale on the scalp, neck, and limbs with truncal erythema, palmoplantar keratoderma and keratoses on the lips, ears, nipples and buttocks.
    Defects in KRT1 are a cause of palmoplantar keratoderma non-epidermolytic (NEPPK) [MIM:600962]. NEPKK is a dermatological disorder characterized by focal palmoplantar keratoderma with oral, genital, and follicular lesions.
    Defects in KRT1 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months.
    Defects in KRT1 are the cause of palmoplantar keratoderma striate type 3 (SPPK3) [MIM:607654]; also known as keratosis palmoplantaris striata III. SPPK3 is a dermatological disorder affecting palm and sole skin where stratum corneum and epidermal layers are thickened. There is no involvement of non-palmoplantar skin, and both hair and nails are normal.
  • Sequence similarities

    Belongs to the intermediate filament family.
  • Post-translational
    modifications

    Undergoes deimination of some arginine residues (citrullination).
  • Cellular localization

    Cell membrane. Located on plasma membrane of neuroblastoma NMB7 cells.
  • Information by UniProt
  • Database links

  • Alternative names

    • 67 kDa cytokeratin antibody
    • CK-1 antibody
    • CK1 antibody
    • Cytokeratin-1 antibody
    • Cytokeratin1 antibody
    • EHK antibody
    • EHK1 antibody
    • Epidermolytic hyperkeratosis 1 antibody
    • EPPK antibody
    • Hair alpha protein antibody
    • K1 antibody
    • K2C1_HUMAN antibody
    • Keratin antibody
    • Keratin type II cytoskeletal 1 antibody
    • Keratin-1 antibody
    • Keratin1 antibody
    • KRT 1 antibody
    • Krt1 antibody
    • KRT1A antibody
    • NEPPK antibody
    • type II cytoskeletal 1 antibody
    • Type II keratin Kb1 antibody
    • Type-II keratin Kb1 antibody
    see all

Images

  • Paraffin-embedded human kidney tissue stained for Cytokeratin 1 using ab232685 at 20 µg/ml in immunohistochemical analysis. DAB staining.

  • Paraffin-embedded human breast cancer tissue stained for Cytokeratin 1 using ab232685 at 20 µg/ml in immunohistochemical analysis. DAB staining.

  • Paraffin-embedded human liver cancer tissue stained for Cytokeratin 1 using ab232685 at 20 µg/ml in immunohistochemical analysis. DAB staining.

  • Anti-Cytokeratin 1 antibody (ab232685) at 2 µg/ml + Recombinant human Cytokeratin 1 protein

    Secondary
    HRP-Linked Guinea pig Anti-Rabbit at 1/2000 dilution

    Predicted band size: 66 kDa

  • All lanes : Anti-Cytokeratin 1 antibody (ab232685) at 2 µg/ml

    Lane 1 : A-375 (human malignant melanoma cell line) cell lysate
    Lane 2 : NCI-H460 (human lung cancer cell line) cell lysate
    Lane 3 : HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate

    Secondary
    All lanes : HRP-Linked Guinea pig Anti-Rabbit at 1/2000 dilution

    Predicted band size: 66 kDa

References

ab232685 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab232685.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up